Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not de...
Guardado en:
Autores principales: | Matteo Nioi, Ernesto d’Aloja, Maurizio Fossarello, Pietro Emanuele Napoli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/23932dc237a1497182bc822524614c1e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021) -
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021) -
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021) -
Safety and efficacy of RNA vaccines: State of the art
por: A. V. Blagov, et al.
Publicado: (2021)